FOXP3 and neoplasm: On day 15 of treatment, we observed a significant upregulation of tumour immunogenicity markers (MHCI and PD-L1), significant increase in the proportion of tumour-infiltrating CD8+ and CD4+/FOXP3- T effector cells as well as the production of IFNγ by CD4+ T cells (Fig. 3e, f).